Cosmos Health Inc. (NASDAQ:COSM), a diversified global healthcare group, has unveiled its financial guidance for the 2026–2029 period, projecting significant growth across all key metrics. The company aims to achieve $200.6 million in revenue by 2029, representing a 207% increase from $65.3 million in 2025, driven by a compound annual growth rate of 32%.
Key Financial Targets for 2029
Cosmos Health expects gross profit to soar by 801% to $71.2 million, with margins expanding from 12.1% to 35.5%. This improvement is attributed to a strategic shift toward high-margin proprietary segments, including nutraceuticals, contract manufacturing, and research and development. Net income is projected to transition from a loss of $19.1 million in 2025 to a profit of $31.0 million by 2029, with profitability anticipated in 2027.
Adjusted EBITDA is forecasted to reach $44.2 million, up from a loss of $3.4 million, while operating cash flow is expected to turn positive in 2027 and more than double to $24.0 million by 2029. The company also projects a balance sheet transformation, with cash increasing 18-fold to $62.9 million, all convertible notes repaid, and stockholders' equity rising 402% to $92.3 million.
Growth Drivers and Strategy
The guidance highlights clear growth drivers, including high-margin proprietary products, expansion of the distribution and manufacturing platform, global partnerships, advancement of the R&D pipeline, AI-driven efficiencies, and disciplined capital allocation. The U.S. market is expected to serve as a new growth engine alongside selective merger and acquisition activity.
Greg Siokas, Chief Executive Officer of Cosmos Health, commented: “We encourage our shareholders to review this guidance report carefully, as it outlines management’s current expectations and strategic priorities for the period ahead.”
Detailed Financial Metrics
- Revenue: From $65.3 million in 2025 to $200.6 million in 2029 (+207%, 32% CAGR)
- Gross Profit: From $7.9 million to $71.2 million (+801%, 73% CAGR)
- Gross Margin: Expanding from 12.1% to 35.5% (+2,340 basis points)
- Net Income: Improving from ($19.1 million) to $31.0 million (+$50.1 million)
- Adjusted EBITDA: From ($3.4 million) to $44.2 million (+$47.6 million)
- Operating Cash Flow: From ($8.4 million) to $24.0 million (+$32.4 million)
- EPS (Non-Diluted): From ($0.42) to $0.73 (+$1.15 per share)
- Total Assets: From $65.5 million to $151.3 million (+131%, 23% CAGR)
- Cash & Equivalents: From $3.5 million to $62.9 million (+18x, 106% CAGR)
- Stockholders’ Equity: From $18.4 million to $92.3 million (+402%, 50% CAGR)
Revenue Breakdown
Revenue growth is expected to be driven by organic expansion across pharmaceutical distribution, accelerating U.S. nutraceutical commercialization through the 18 Series, international expansion of Sky Premium Life, contract manufacturing scale-up at Cana Laboratories, and the expected commercial launch of CCX.
Profitability Outlook
Net income improvement reflects revenue growth, gross margin expansion, operating leverage, and increasing cost efficiencies. Adjusted EBITDA margin is projected to reach 22.1% by 2029, driven by strong revenue growth and expanding profitability in higher-margin business segments.
Cosmos Health believes this financial trajectory could create a powerful compounding effect across its operations, balance sheet, and profitability profile, supporting its long-term vision of building a leading diversified healthcare platform.
